Drug intelligence / Profile preview

Xiao'er Xiangru Keli

Development stage: Unknown
Lead developer: Yili Group
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Xiao'er Xiangru Keli is a Traditional Chinese Medicine (TCM) granule formulation developed by Yili Pharmaceutical for the treatment of pediatric acute upper respiratory tract infections. It is specifically indicated for patients presenting with the 'wind-heat with dampness' syndrome. The medication is derived from botanical extracts, with *Xiangru* (Herba Moslae) as a key component, traditionally used to clear summer-heat and resolve dampness. Clinical development is focused on establishing the optimal dosage and safety profile in the pediatric population.

Brand names: Xiao'er Xiangru Keli
Other names: Xiao'er Xiangru Granules

Beyond the preview

Go deeper on Xiao'er Xiangru Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiao'er Xiangru Keli.

Explore the full profile